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2298Insulin Status and Vascular Responses to Weight Loss in ObesityObjectives TSeehe aim of this study was to determine whether the effects of weight loss on arterial function are differentially
modiﬁed by insulin status.Background Clinical studies suggest that plasma insulin levels may predict the extent of cardiovascular beneﬁt achieved with
weight loss in obese individuals, but mechanisms are currently unknown.Methods We prospectively followed 208 overweight or obese patients (body mass index [BMI] 25 kg/m2) receiving
medical/dietary (48%) or bariatric surgical (52%) weight-loss treatment during a median period of 11.7 months
(interquartile range: 4.6 to 13 months). We measured plasma metabolic parameters and vascular endothelial
function using ultrasound at baseline and following weight-loss intervention and stratiﬁed analyses by median
plasma insulin levels.Results Patients age 45  1 years, with BMI 45  9 kg/m2, experienced 14  14% weight loss during the study
period. In individuals with higher baseline plasma insulin levels (above median >12 mIU/ml; n ¼ 99), 10%
weight loss (compared with <10%) signiﬁcantly improved brachial artery macrovascular ﬂow-mediated
vasodilation and microvascular reactive hyperemia (p < 0.05 for all). By contrast, vascular function did not
change signiﬁcantly in the lower insulin group (12 mIU/ml; n ¼ 109) despite a similar degree of weight loss.
In analyses using a 5% weight loss cut point, only microvascular responses improved in the higher insulin group
(p ¼ 0.02).Conclusions Insulin status is an important determinant of the positive effect of weight reduction on vascular function with
hyperinsulinemic patients deriving the greatest beneﬁt. Integrated improvement in both microvascular and
macrovascular function was associated with 10% weight loss. Reversal of insulin resistance and endothelial
dysfunction may represent key therapeutic targets for cardiovascular risk reduction in obesity. (J Am Coll Cardiol
2013;62:2297–305) ª 2013 by the American College of Cardiology FoundationObesity has emerged as one of the most critical healthcare
problems in the United States and worldwide, with nearly
70% of the U.S. population currently overweight or obese
(1). Of major concern are data showing disproportionate
surges in categories of severe obesity (body mass index
[BMI] 40 kg/m2), which tripled its prevalence during the
1990s (2). Nearly one-third of adults (1) and 17% of chil-
dren (3) in the United States are now obese, with 65 million
additional cases estimated by 2030 (4). Although obesity
confers serious health concerns and increased all-cause
mortality, the vast majority of deaths are due to cardiovas-
cular causes such as ischemic heart disease and stroke (5,6).page 2306Thus, there is a pressing need to elucidate potential mech-
anisms that link excess adiposity to cardiovascular risk
and identify groups most likely to beneﬁt from targeted
treatment.
Although obesity prevention is likely to provide the
optimal public health solution, there is obvious interest in
promoting weight loss as a therapeutic strategy to reverse
obesity-related cardiometabolic risk (5). However, few
clinical studies have explicitly examined the relationship
between intentional weight loss and cardiovascular mortality.
The most convincing data emerged recently from the
SOS (Swedish Obese Subjects) study showing reduced
long-term cardiovascular mortality following bariatricsurgery, largely owing to decreased myocardial infarction
risk (7). Although speciﬁc mechanisms for cardiovascular
beneﬁt remain unknown, plasma insulin appeared to
emerge as a primary determinant of cardiac events,
providing evidence that insulin resistance may contribute
signiﬁcantly to the pathogenesis of vascular disease in
obesity (7).
The vascular endothelium plays a key role in the regula-
tion of arterial tone, blood ﬂow, inﬂammation, and throm-
bosis (8,9). Endothelial phenotype serves as a barometer of
overall vascular health and displays impairment in insulin-
resistant states, and severity of both microvascular and
macrovascular dysfunction independently predict future
cardiovascular events (8,10–14). The purpose of the study
was to determine whether the effects of weight loss on
arterial function are differentially modiﬁed by insulin status
in overweight and obese individuals undergoing weight-
reduction intervention.Methods
Patients. Overweight adult men and women (age 18
years) with BMI25 kg/m2 seeking weight-loss treatment at
the Boston Medical Center Nutrition and Weight
Management Clinic (n ¼ 208) were prospectively followed.
This hospital-based weight loss intervention program uses
a comprehensive approach for obesity management using
behavioral, dietary, medical, and/or surgical treatments that
are individualized based on clinical and patient decisions.
Abbreviations
and Acronyms
BMI = body mass index
FMD = ﬂow-mediated
dilation
HbA1c = glycosylated
hemoglobin
HDL = high-density
lipoprotein
HOMA = homeostasis model
assessment
LDL = low-density lipoprotein
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2299Interventions comply with established National Heart, Lung
and Blood Institute clinical guidelines (15) and included
medical therapy with dietary/lifestyle modiﬁcation (n ¼ 100;
48%) and bariatric surgery (n ¼ 108; 52%). Low-
carbohydrate Atkins-type or Mediterranean diets were
not speciﬁcally prescribed. Nearly all bariatric surgical pro-
cedures comprised the Roux-en-Y gastric bypass operation
(n ¼ 106); 2 patients underwent laparoscopic adjustable
gastric banding. The analyses represent data from patients
collected to date from an ongoing prospective cohort
study designed to examine vascular responses to weight loss.
Patients with unstable medical conditions such as recent
coronary syndromes (within 6 months), congestive heart
failure, systemic infection, acute illness, malignancy, or
pregnancy were excluded. The study was approved by the
Boston Medical Center Institutional Review Board, and all
patients gave written informed consent.
Vascular function studies. Each patient underwent a
forearm brachial artery ultrasound vascular study twice,Table 1 Baseline Clinical Characteristics Stratiﬁe
Lower Insulin12 mIU/
(n ¼ 109)
Age, yrs 44.8  11
Female, % 85
Race/ethnicity, %
White 52
African American 30
Hispanic 16
Other 2
Weight, kg 115  26
BMI, kg/m2 42  8
SBP, mm Hg 130  15
DBP, mm Hg 74  10
Total cholesterol, mg/dl 191  36
Triglycerides, mg/dl 89 (67–146)
LDL-cholesterol, mg/dl 117  31
HDL-cholesterol, mg/dl 50  13
Glucose, mg/dl 92 (87–100)
Insulin, mIU/ml 8 (6–10)
HOMA 2.0 (1.4–2.4)
HbA1c, % 6.0  1.2
Vascular function parameter, %
Hyperemic ﬂow increase 779  400
FMD 9.2  4.5
Comorbidity, %
Hypercholesterolemia 34
Diabetes mellitus* 21
Coronary artery disease 4
Hypertension 39
Medical therapy, %
Antihypertensive 43
Lipid-lowering 19
Hypoglycemicy 17
Insulin 3
Values are mean  SD, %, or median (interquartile range). *Diabetes mellitus
the lower insulin group was diagnosed with type 1 diabetes. yExcluded insul
BMI ¼ body mass index; DBP ¼ diastolic blood pressure; FMD ¼ ﬂow-me
lipoprotein; HOMA ¼ homeostasis model assessment; LDL ¼ low-density lipperformed at baseline before life-
style and/or surgical intervention
and follow-up after a median of
11.7months (interquartile range:
4.6 to 13.0). Vascular studies
were performed during a fasting
state in a quiet, temperature-
controlled room under resting
conditions by trained sonogra-
phers (16). Brachial vasomotor
responses were examined using
a noninvasive, standardized
method of ultrasound with
a Toshiba Powervision 6000 system (Toshiba Medical,
Tustin, California). Brachial artery 2-dimensional diameter
(mm) images and pulse Doppler ﬂow velocity (cm/s)
were measured at the antecubital crease. Brachial ﬂow-
mediated dilation (FMD) following a 5-min cuff occlu-
sion in an upper arm position served as a measure ofd by Plasma Insulin Level
ml Higher Insulin>12 mIU/ml
(n ¼ 99) p Value
44.9  11 0.92
78 0.16
0.49
58
21
19
2
131  29 <0.0001
47  9 <0.0001
129  14 0.81
72  10 0.11
186  38 0.37
130 (89–171) <0.001
112  33 0.24
45  9 <0.001
100 (91–116) 0.05
19 (14–26) <0.0001
4.6 (3.5–6.9) <0.0001
6.5  1.5 0.01
666  395 0.04
8.4  4.8 0.23
42 0.21
43 <0.001
15 0.01
57 0.01
59 0.03
30 0.06
32 0.01
8 0.12
included a medical diagnosis of type 1 or 2 diabetes. One participant in
in use.
diated dilation; HbA1c ¼ glycosylated hemoglobin; HDL ¼ high-density
oprotein; SBP ¼ systolic blood pressure.
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2300endothelium-dependent macrovascular function, expressed
as percent change in brachial diameter before and 60 s
after cuff occlusion. Brachial artery reactive hyperemia
expressed as the percent change in hyperemic forearm
blood ﬂow increase after cuff occlusion served as the index
measure of endothelium-dependent microvascular function
(10,12,17,18).
Clinical and metabolic measures. Clinical characteristics,
including blood pressure, height, weight, and BMI, were
recorded on the same day as the vascular studies. Weight
was measured using a calibrated scale (Ohaus, Pine Brook,
New Jersey). Biochemical analyses including lipid, glucose,
and insulin levels; homeostasis model assessment of insulin
resistance (HOMA); and glycosylated hemoglobin (HbA1c)
were quantiﬁed from blood samples collected in a fasting
state during each visit. Medications were recorded for all
visits, including antihypertensive, hypoglycemic, and lipid-
lowering regimens.
Statistical analyses. Analyses were completed using SAS for
Windows, version 9.1 (SAS Institute Inc., Cary, North
Carolina). Data are presented as mean  SD, median with
interquartile range, or proportions (%), unless otherwise
indicated. The primary outcome variables were FMD (%) and
hyperemic ﬂow increase (%). Absolute change was calculated
as the numerical value difference between baseline and follow-
up. Histograms and normal probability plots were used to
determine whether continuous variables were normally
distributed or skewed. Baseline triglyceride, glucose, and
insulin levels and HOMA were nonnormally distributed and
analyzed following natural log transformation. Informed by
data from the SOS study (7), our a priori hypothesis was that
the effects of weight loss on vascular function would differ by
plasma insulin levels; as such, we stratiﬁed our analyses by
baseline insulin level. Participants were dichotomized into 2
groups based on median baseline insulin concentration, for
which the lower insulin group was deﬁned as 12 mIU/ml
(n¼ 109) and higher insulin group>12 mIU/ml (n¼ 99). InTable 2 Effect of 10% Weight Loss on Clinical Parameters Stratiﬁed
Lower Insulin 12 mIU/ml
Weight Loss <10%
(n ¼ 59)
Weight Loss 10%
(n ¼ 50)
BMI, kg/m2 1.4 (0.5) 10.3 (0.6)
SBP, mm Hg 0 (2.1) 8.4 (2.4)
DBP, mm Hg 0.8 (1.2) 1.7 (1.4)
Total cholesterol, mg/dl 6.2 (4) 13.9 (4.2)
Triglycerides, mg/dl 6.8 (5.9) 31.7 (6.2)
LDL-cholesterol, mg/dl 4.3 (3.3) 12 (3.5)
HDL-cholesterol, mg/dl 0 (1.5) 3.9 (1.6)
Glucose, mg/dl 1.7 (2.7) 7.3 (2.9)
Insulin, mIU/ml 1.9 (0.9) 3 (0.9)
HOMA 0.34 (0.21) 0.82 (0.22)
HbA1c, % 0.14 (0.07) 0.51 (0.07)
Values are mean (SE) adjusted for baseline values for age, BMI, and the outcome of interest. Analysi
dichotomous weight-loss groups.
Abbreviations as in Table 1.separate models, analysis of covariance (proc GLM in SAS)
was used to examine the effect of 5% or 10% weight-loss cut
points, based on expert target recommendations for weight
reduction in the management of obesity (15) and on changes
in vascular and clinical parameters stratiﬁed by insulin status.
Baseline age and BMI were included as covariates in all
models. In addition, models were adjusted for baseline values
for the outcome of interest. For example, in analyses exam-
ining the effect of 10% weight loss on change in FMD,
baselineFMDwas included as a covariate. The exposureswere
treated as dichotomous variables (e.g., 10% weight loss or
not) and outcomes and covariates as continuous ones. We
included interaction terms in models to formally test for effect
modiﬁcation of the association between weight loss and
vascular function by baseline insulin status. Medication
changes were analyzed across insulin strata and weight-loss
categories. All group differences were examined using the
Student t test, chi-square test, or Fisher exact test as appro-
priate and within weight-loss group changes by paired
Student t tests. Partial Pearson correlation adjusted for base-
line age andBMIwas used to examine the association between
changes in clinical data and vascular function parameters. For
all analyses, a p value <0.05 was considered statistically
signiﬁcant.Results
Study population. A total of 208 patients (mean age 45 11
years; 82% female; BMI 45 9 kg/m2) were enrolled. Nearly
all participants were obese, with BMI >30 kg/m2 (n ¼ 205;
99%). Participants were 55% white, 26% African American,
and 17% Hispanic, reﬂecting demographics of the general
population seekingweight-loss treatment in our urban tertiary
center. Approximately half (n¼ 109; 52%) of the participants
underwent bariatric surgery, and 48% (n ¼ 99) received
lifestyle intervention alone. For the entire group, median
follow-up was 11.7 months and mean weight loss 14  14%.by Insulin Level
Higher Insulin >12 mIU/ml
p Value
Weight Loss <10%
(n ¼ 37)
Weight Loss 10%
(n ¼ 62) p Value
<0.0001 0.7 (0.7) 12.4 (0.5) <0.0001
0.01 3.2 (2.5) 3 (1.9) 0.06
0.65 0.2 (1.5) 2.8 (1.1) 0.17
0.20 5.4 (5.2) 13.7 (3.8) 0.21
0.01 7.3 (10.0) 35.8 (7.4) 0.03
0.12 4.2 (4.3) 10 (3.1) 0.28
0.10 0.2 (1.9) 3.6 (1.4) 0.16
0.18 13.2 (5.4) 13.5 (4.1) <0.001
<0.001 2.9 (1.8) 14.2 (1.4) <0.0001
<0.001 0.10 (0.95) 4.33 (0.74) <0.001
<0.001 0.07 (0.15) 0.95 (0.11) <0.0001
s of covariance was used to determine the difference in change in clinical parameters between
Figure 1 Effect of 10% Weight Loss on Vascular Function
Brachial artery ﬂow-mediated (FMD) vasodilation and hyperemic ﬂow improved
signiﬁcantly in the baseline higher insulin, but not lower insulin group. Values
represent mean (95% conﬁdence interval) difference in change in vascular function
between 10% versus <10% weight loss, adjusted for baseline age, body mass
index, and vascular function. *p < 0.05.
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2301Baseline clinical data stratiﬁed by median plasma insulin
concentration are displayed in Table 1. Patients in the higher
insulin group (>12 mIU/ml) had higher BMI, triglyceride
levels, and HOMA and lower high-density lipoprotein
(HDL)-cholesterol values (p < 0.05). Prevalence of diabetes
mellitus, coronary artery disease, hypertension, and medica-
tions used to treat these conditions were also higher in this
group. Microvascular function as measured by brachial artery
hyperemic ﬂow (reactive hyperemia) was lower in the higher
insulin group (p < 0.05), whereas brachial FMD was
comparable between insulin strata.
Weight loss and clinical parameters. As shown in
Table 2, 10% weight change was associated with a signif-
icant decline in BMI, HOMA, HbA1c, and insulin and
triglyceride levels in both higher and lower baseline insulin
categories (p < 0.05 for all). A threshold cut point of 5%
weight loss induced similar, but less pronounced, metabolic
changes (data not shown). Whereas individuals with higher
plasma insulin concentrations achieved improvements in
metabolic variables that were directionally similar to those in
the lower insulin group, incremental decrease in insulin
levels and HOMA among those with 10% weight loss
was more than 4 times greater in the higher insulin group
(14.2 and 4.3 mIU/ml, respectively) as compared with
the lower insulin group (3.0 and 0.82 mIU/ml, respec-
tively) despite a comparable degree of weight change. The
proportion of patients who underwent surgical intervention
was similar in lower compared with higher insulin categories
(47% vs. 58%; p ¼ 0.12). In individuals who lost 10%
weight (n ¼ 112), weight change was similar between lower
and higher insulin strata (24.0  10.0% vs. 25.8  10.1%,
respectively; p ¼ 0.34). However, the majority of patients
achieved 10% weight loss as a result of bariatric surgical
intervention, which did not differ between higher and lower
insulin groups (87% vs. 88%; p ¼ 0.89).
Weight loss and vascular function. As shown in Figure 1,
in models adjusted for baseline age, BMI, and vascular
function, 10% weight change signiﬁcantly improved
hyperemic blood ﬂow (microvascular function) and FMD
(macrovascular function) in patients with higher baseline
insulin (both p < 0.05), whereas 5% weight change was only
associated with improved microvascular responses (p ¼ 0.02)
(Fig. 2). Although a trend for increased reactive hyperemia
was observed (p ¼ 0.08), similar degrees of weight loss
did not signiﬁcantly alter microvascular or macrovascular
responses in patients with lower baseline insulin levels. The
inclusion of change in hyperemic ﬂow increase as a covariate
in models predicting change in FMD did not alter these
relationships, suggesting that improvement in FMD in the
higher insulin strata was not exclusively mediated by
changes in ﬂow. Results for 10% weight loss and vascular
improvement were similar after excluding patients using
insulin clinically (n ¼ 11) and adjustment for changes in
medications, blood pressure, lipids, glucose, HOMA, and
HbA1c in analysis of covariance models, thus demonstrating
that these parameters did not confound the ﬁndings. In
Figure 2 Effect of 5% Weight Loss on Vascular Function
Brachial artery hyperemic ﬂow improved signiﬁcantly only in the baseline higher
insulin group. Values represent mean (95% conﬁdence interval) difference in
change in vascular function between 5% versus <5% weight loss, adjusted for
baseline age, body mass index, and vascular function. *p < 0.05. Abbreviation as
in Figure 1.
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2302formal tests of interaction, the association between 10%
weight loss and change in FMD signiﬁcantly differed by
baseline insulin status (p ¼ 0.04), and there wasa suggestion of effect modiﬁcation with change in hyper-
emic ﬂow increase set as the dependent variable (p ¼ 0.1).
As metabolic improvements occurred with weight loss,
individuals discontinued medications for the treatment of
hypertension, dyslipidemia, andglucose intolerance as displayed
in Table 3. A 10% weight reduction was associated with
greater abatement in medication use compared with <10%
weight change. There was a strong trend for reduced hypogly-
cemic drug use following weight loss in the higher versus lower
insulin group (p ¼ 0.05); otherwise, there were no signiﬁcant
differences in discontinuation of antihypertensive or lipid-
lowering treatment across insulin strata.
Metabolic and vascular effects stratiﬁed by weight loss.
Individuals who achieved 10% weight loss (n ¼ 112) had
signiﬁcantly improved total cholesterol, low-density lipopro-
tein (LDL)-cholesterol, triglyceride, HDL-cholesterol,
glucose, and insulin levels and HOMA (p < 0.05 vs. base-
line). Compared with participants with <10% weight loss,
there were more favorable changes in triglyceride (p ¼ 0.002),
HDL-cholesterol (p ¼ 0.04), glucose (p ¼ 0.003), insulin
(p < 0.0001) levels, HOMA (p < 0.0001), and HbA1c
(p < 0.0001), and trend toward improved LDL-cholesterol
(p ¼ 0.06) and total cholesterol (p ¼ 0.09) levels (data not
shown). Patients with10% weight loss exhibited 206% (95%
CI: 99% to 313%; p¼ 0.0002) improvement in hyperemic ﬂow
increase compared with <10% weight decline, but no group
difference in change in FMD was detected (p ¼ 0.25). In
analyses adjusted for age and BMI, changes in microvascular
function correlated negatively with change in insulin levels
(r ¼ 0.19; p ¼ 0.01), HOMA (r ¼ 0.16; p ¼ 0.03), and
LDL-cholesterol levels (r ¼ 0.19; p ¼ 0.01), and macro-
vascular function correlated positively with HDL-cholesterol
levels (r ¼ 0.15; p ¼ 0.04).
Discussion
In a cohort of obese patients undergoing weight-reduction
therapy, baseline insulin status was a key determinant of the
positive effects of weight loss on vascular function, with
higher-risk hyperinsulinemic patients deriving the greatest
beneﬁt. A modest 5% decrease in body weight improved
cardiovascular risk factors and microvascular function in
patients with higher insulin levels, and weight reduction
of 10% reversed metabolic dysfunction to a greater extent
and improved both microvascular and macrovascular vaso-
dilator responses. Given the key role of vascular homeostasis
in mitigating cardiovascular risk, our ﬁndings suggest that
reversal of insulin resistance and endothelial dysfunction
may be mechanistically intertwined and represent important
therapeutic targets in obesity.
Few studies have examined the relationship between
intentional weight loss and cardiovascular mortality. A 12-
year observational study in overweight women reported that
weight change with lifestyle modiﬁcation reduced mortality,
with greatest impact in high-comorbidity subsets (19).
Similarly, retrospective analysis of bariatric surgical patients
Table 3
Medication Discontinuation Following Weight Loss Across Treatment Classes
Stratiﬁed by Insulin Status
Lower Insulin 12 mIU/ml
Weight Loss <10%, n ¼ 59 10%, n ¼ 50 p Value
Antihypertensive 10 (6) 26 (13) 0.03
Lipid-lowering 0 (0) 20 (10) 0.0002
Hypoglycemic 2 (1) 20 (10) 0.002
Higher Insulin >12 mIU/ml
Weight Loss <10%, n ¼ 37 10%, n ¼ 62 p Value
Antihypertensive 3 (1) 37 (23) <0.0001
Lipid-lowering 3 (1) 21 (13) 0.01
Hypoglycemic 0 (0) 36 (22) <0.0001
Values are % discontinuation (n).
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2303showed improved cardiovascular survival during a 7.1-year
follow-up period (20). The strongest evidence to date comes
from the prospective SOS study, which recently reported 15-
year follow-up data demonstrating nearly 30% reduction in
long-term risk of myocardial infarction and stroke with
bariatric weight loss (7,21). Surprisingly, although neither
BMI nor improvement in many traditional risk factors were
linked to cardiovascular beneﬁt, secondary analyses identiﬁed
baseline plasma insulin levels as the primary determinant of
cardiovascular risk. Our results build upon this observation
because the notion that insulin status stratiﬁes vascular
improvement was evident from our study, prompting recog-
nition that the reduced number of cardiovascular events
following weight loss may be tied to mechanisms of improved
insulin sensitivity and arterial homeostasis.
Although prior small studies showed that vascular function
improved with weight decline, differential associations by
insulin status have not been speciﬁcally explored (22–25).
Circulating asymmetrical dimethylarginine levels, an endog-
enous endothelial nitric oxide synthase inhibitor, decline pref-
erentially in insulin-resistant patients followingweight loss (26).
We similarly observed that vascular beneﬁts of weight reduction
were primarily manifest in hyperinsulinemic patients. From
a clinical perspective, several important points can be empha-
sized from our study. First, baseline differences in insulin status
did not appear to modulate extent of weight loss achieved.
Second, it was evident that not all obese individuals gained equal
metabolic or vascular beneﬁt from weight reduction. Third,
vascular improvement did not appear to be confounded by
medication changes that were similar across insulin strata.
Fourth, our data provide a potential mechanism for the SOS
study ﬁndings that conﬁne the effectiveness of weight loss in
reducing cardiac events to high insulin categories. Lastly, our
results also suggest that 10% weight change may be required
for integrated improvement inmicrovascular andmacrovascular
functions, which further supports National Heart, Lung and
Blood Institute recommendations targeting 10% weight
reduction for medical beneﬁts (15).
Elevated circulating insulin levels likely reﬂect a patho-
physiological state of systemic insulin resistance that is
associated with vascular endothelial dysfunction, arterial
inﬂammation, oxidative stress, and accelerated atherosclerosis(27–31). The magnitude of insulin resistance varies widely
among obese individuals, and higher insulin concentrations
are linked to dysfunctional vascular phenotypes in both
coronary and peripheral circulations (32,33). Animal and
human data show that pathological abnormalities involve
defects in vascular insulin signaling, such as the insulin
receptor substrate 1/phosphoinositide 3-kinase/Akt pathway
associated with impaired endothelial nitric oxide synthase
activity and nitric oxide bioaction, and expression of proin-
ﬂammatory, prothrombotic, and vasoconstrictive mediators
that support a proatherogenic vascular phenotype (30). These
abnormalities manifest, in part, as defects in both microvas-
cular and macrovascular endothelial function that have been
prospectively and independently linked to adverse cardiovas-
cular events such as myocardial infarction and stroke
(10,12,34,35).
Although our results expand our understanding of the
complex relationship among obesity, insulin resistance, and
arterial disease, further questions remain. Evidence is
mounting that bariatric surgery is more effective than
conventional treatment for durable weight loss and diabetes
remission (36,37). As expected, bariatric intervention was
more effective in achieving rapid and more extensive weight
loss during the follow-up period (z1 year) compared with
conventional therapy in our cohort. Although our study was
not designed to compare weight intervention methods, the
proportion of individuals treated surgically was the same
across insulin strata, suggesting that vascular beneﬁts were not
a consequence of differential operative intervention. In that
regard, recent ﬁndings from the Look AHEAD (Action for
Health in Diabetes) study reported that although intensive
lifestyle modiﬁcation through diet and exercise induced 6%
weight loss at 9.6 years with positive health beneﬁts, the
number of cardiovascular events was not lowered (38). In
addition, several dietary intervention studies in which mean
weight loss was <10% reported no signiﬁcant macrovascular
improvement (39,40). This adds further debate, not only to
the search for optimal weight-loss strategy, but also regarding
the minimal amount of weight change required to elicit
comprehensive health beneﬁts.
Because the most important health risk of obesity is
the development of cardiovascular disease, the clinical
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drive, in part, the association between obesity and cardio-
vascular risk raises issues regarding treatment strategies. As
such, pharmacological therapies for insulin sensitization
have displayed variable cardiovascular effects (41–43).
Enhanced insulin sensitivity achieved by weight loss likely
involves additional complex beneﬁcial mechanisms mediated
by modulation of fat tissue phenotypes, reduction of
adipose-derived inﬂammatory cytokines, fatty acid mobili-
zation, and hormonal shifts (23,44–46). In our cohort,
changes in microvascular function were more sensitive to
weight modiﬁcation, and insulin resistance correlated more
closely with microvascular responses than conduit vessel
function. How speciﬁc therapeutic strategies intertwine with
favorable modiﬁcation of vascular phenotypes is clinically
important and warrants further investigation.
Study limitations. The present study has several limitations.
First, the study was not randomized, although interventions
were based on clinical decisions that likely reﬂect quotidian
practice. Despite its observational nature, the prospective
design maintained temporal relationship between alterations
in metabolic parameters and vascular function during the
follow-up period. Second, the study did not examine cardiac
outcome data, which limits generalization regarding ab-
solute risk. We recognize that forearm hyperemia repre-
sents a complex physiological response that is only partly
endothelium dependent. However, our endpoints of arterial
function as surrogates of cardiovascular risk have been
prospectively validated in multiple outcomes studies (11).
Third, we used an arbitrary cutoff (median split) to categorize
our participants into higher and lower baseline insulin cate-
gories. Insulin values of our sample of severely obese partici-
pants were elevated compared with normal levels reported in
community-based studies (47). Additional studies with large
sample sizes and conducted in obese populations are needed
to explore alternative plasma insulin cutoffs that may maxi-
mize the differential relationships observed in our study.
Lastly, sustainability of relatively short-term (w1 year)
vascular changes in our cohort has not been examined in the
long-term and requires continued investigation.Conclusions
Our results suggest that reduction of cardiovascular risk in
obesity may vary as a function of reversing insulin resistance
and vascular endothelial dysfunction. Although we empha-
size that intentional weight loss of any kind averts a multi-
tude of health risks associated with excess adiposity, our data
suggest that attempts to reduce cardiovascular risk by weight
reduction should be particularly emphasized in obese
hyperinsulinemic individuals.
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